Guardant Health Inc（GH）の財務GHGuardant Health Inc

Guardant Health, Inc. (GH) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Oncology, accounting for 65.4% of total sales, equivalent to $219.10M. Other significant revenue streams include Biopharma and data and Screening. Understanding this composition is critical for investors evaluating how GH navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Guardant Health, Inc. maintains a gross margin of 65.39%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -38.55%, while the net margin is -35.87%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively GH converts its operational activities into shareholder value.

In the context of the broader market, GH competes directly with industry leaders such as STE and WST. With a market capitalization of $22.06B, it holds a significant position in the sector. When comparing efficiency, GH's gross margin of 65.39% stands against STE's 45.84% and WST's 37.74%. Such benchmarking helps identify whether Guardant Health, Inc. is trading at a premium or discount relative to its financial performance.

Guardant Health's total revenue has shown consistent growth, with Q2 2026 revenue reported at $334.98 million, up from $281.27 million in Q4 2025. However, the company continues to report net losses, with a net income of -$120.14 million in Q2 2026.